GRAL

GRAIL, Inc. Common Stock

25.10 USD
-0.44
1.72%
At close Apr 1, 4:00 PM EDT
After hours
25.03
-0.07
0.28%
1 day
-1.72%
5 days
-19.94%
1 month
-30.91%
3 months
40.07%
6 months
89.43%
Year to date
40.07%
1 year
83.75%
5 years
83.75%
10 years
83.75%
0
Funds holding %
of 7,398 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

106% more call options, than puts

Call options by funds: $9.3M | Put options by funds: $4.51M

70% more capital invested

Capital invested by funds: $280M [Q3] → $476M (+$196M) [Q4]

57% more first-time investments, than exits

New positions opened: 77 | Existing positions closed: 49

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

8.65% more ownership

Funds ownership: 70.6% [Q3] → 79.25% (+8.65%) [Q4]

7% more funds holding

Funds holding: 302 [Q3] → 322 (+20) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 78

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$20
20%
downside
Avg. target
$20
20%
downside
High target
$20
20%
downside

1 analyst rating

positive
0%
neutral
100%
negative
0%
Morgan Stanley
Tejas Savant
21% 1-year accuracy
4 / 19 met price target
20%downside
$20
Equal-Weight
Maintained
18 Mar 2025

Financial journalist opinion

Neutral
PRNewsWire
1 month ago
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MENLO PARK, Calif. , Feb. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 108,450 shares of GRAIL's common stock to 15 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Neutral
PRNewsWire
1 month ago
GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing
MENLO PARK, Calif. , Feb. 25, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, has partnered with award-winning actress Kate Walsh to launch Generation Possible, an educational initiative to raise awareness of multi-cancer early detection (MCED) testing.
GRAIL Partners With Actress Kate Walsh for Generation Possible to Raise Awareness of Multi-Cancer Early Detection Testing
Neutral
PRNewsWire
1 month ago
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
MENLO PARK, Calif. , Feb. 21, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the TD Cowen 45th Annual Health Care Conference in Boston on Tuesday, Mar. 4 at 9:10 a.m.
GRAIL to Present at TD Cowen 45th Annual Health Care Conference
Neutral
Seeking Alpha
1 month ago
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
GRAIL, Inc. (NASDAQ:GRAL ) Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ET Company Participants Bob Ragusa - Chief Executive Officer and Board Member Aaron Freidin - Chief Financial Officer Joshua Ofman - President Sir Harpal Kumar - President of International Business and BioPharma Conference Call Participants Doug Schenkel - Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the GRAIL Fourth Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.
GRAIL, Inc. (GRAL) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
1 month ago
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Sold More than 137,000 Galleri® Tests in 2024, Growing U.S. Galleri Revenue 45% Year-Over-Year to $108.6 Million Completed Study Visits for Two Registrational Studies in July to Support Modular PMA Submission for Galleri On Track for Continued Commercial Growth in 2025 with TRICARE Coverage and Recent Announcement of Quest Integration Moderated Cash Burn, Ending 2024 with a Cash Position of $767M, Extending Runway into 2028 MENLO PARK, Calif. , Feb. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2024 and provided business updates.
GRAIL Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
PRNewsWire
1 month ago
GRAIL to Announce Fourth Quarter 2024 Financial Results
MENLO PARK, Calif. , Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the fourth quarter 2024 following the close of market on Thursday, Feb. 20, 2025.
GRAIL to Announce Fourth Quarter 2024 Financial Results
Neutral
PRNewsWire
1 month ago
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri   Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience  MENLO PARK, Calif. and SECAUCUS, N.J.
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
Positive
Investopedia
2 months ago
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Grail (GRAL) shares could remain in focus after surging to a new record high on Friday to cap off a huge week of gains amid optimism about the medical technology company's early-detection cancer screening blood tests.
Watch These Grail Price Levels After Med Tech Company's Stock Soared 64% Last Week
Positive
Investopedia
2 months ago
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Shares of Grail, Inc. (GRAL) surged 20% intraday Wednesday, putting the medical technology company above the likes of Arm Holdings (ARM) and Netflix (NFLX) to be the biggest gainer in the Nasdaq 100 index in recent trading.
Early Cancer Detection Firm Grail Leads Nasdaq Gainers as Stock Jumps 20%
Neutral
PRNewsWire
2 months ago
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Analysis of Patient Reported Outcomes From PATHFINDER Indicate Minimal Patient Distress Associated with Multi-Cancer Early Detection Testing MENLO PARK, Calif. , Jan. 13, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that patient-reported outcomes (PRO) assessing patient perspectives from the PATHFINDER study were published in Lancet Oncology.
Patient Reported Outcomes for GRAIL's Galleri® Multi-Cancer Early Detection Blood Test Published in Lancet Oncology
Charts implemented using Lightweight Charts™